209 related articles for article (PubMed ID: 29161241)
1. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
[TBL] [Abstract][Full Text] [Related]
5. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
[TBL] [Abstract][Full Text] [Related]
6. Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib.
Fazio N; Kulke M; Rosbrook B; Fernandez K; Raymond E
Target Oncol; 2021 Jan; 16(1):27-35. PubMed ID: 33411058
[TBL] [Abstract][Full Text] [Related]
7. Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.
Lee L; Ito T; Igarashi H; Miki M; Fujimori N; Kawabe K; Jensen RT; Ogawa Y
Cancer Chemother Pharmacol; 2018 Jan; 81(1):163-169. PubMed ID: 29164297
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
Faivre S; Niccoli P; Castellano D; Valle JW; Hammel P; Raoul JL; Vinik A; Van Cutsem E; Bang YJ; Lee SH; Borbath I; Lombard-Bohas C; Metrakos P; Smith D; Chen JS; Ruszniewski P; Seitz JF; Patyna S; Lu DR; Ishak KJ; Raymond E
Ann Oncol; 2017 Feb; 28(2):339-343. PubMed ID: 27836885
[TBL] [Abstract][Full Text] [Related]
9. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
Vinik A; Bottomley A; Korytowsky B; Bang YJ; Raoul JL; Valle JW; Metrakos P; Hörsch D; Mundayat R; Reisman A; Wang Z; Chao RC; Raymond E
Target Oncol; 2016 Dec; 11(6):815-824. PubMed ID: 27924459
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
Invest New Drugs; 2013 Oct; 31(5):1265-74. PubMed ID: 23269537
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
Valle JW; Borbath I; Rosbrook B; Fernandez K; Raymond E
Future Oncol; 2019 Apr; 15(11):1219-1230. PubMed ID: 30701988
[TBL] [Abstract][Full Text] [Related]
12. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
Pellat A; Dreyer C; Couffignal C; Walter T; Lombard-Bohas C; Niccoli P; Seitz JF; Hentic O; André T; Coriat R; Faivre S; Zappa M; Ruszniewski P; Pote N; Couvelard A; Raymond E
Neuroendocrinology; 2018; 107(1):24-31. PubMed ID: 29518779
[TBL] [Abstract][Full Text] [Related]
14. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
16. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
[TBL] [Abstract][Full Text] [Related]
17. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
Blumenthal GM; Cortazar P; Zhang JJ; Tang S; Sridhara R; Murgo A; Justice R; Pazdur R
Oncologist; 2012; 17(8):1108-13. PubMed ID: 22836448
[TBL] [Abstract][Full Text] [Related]
18. Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
Ishak KJ; Rael M; Hicks M; Mittal S; Eatock M; Valle JW
J Comp Eff Res; 2018 Oct; 7(10):947-958. PubMed ID: 30168349
[TBL] [Abstract][Full Text] [Related]
19. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice.
Lahner H; Rinke A; Unger N; Poeppel TD; Kühl H; Lehmann N; Führer D
Horm Metab Res; 2016 Sep; 48(9):575-80. PubMed ID: 27101094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]